The pathological process in Alzheimer's disease (AD) involves amyloid beta
(A beta) deposition and neuronal cell degeneration. The neurotoxic AP pepti
de is derived from the amyloid precursor protein (APP), a member of a large
r gene family including the amyloid precursor-like proteins, APLP1 and APLP
2. The APP and APLP2 molecules contain metal binding sites for copper and z
inc. The zinc binding domain (ZnBD) is believed to have a structural rather
than a catalytic role. The activity of the copper binding domain (CuBD) is
unknown, however, APP reduces copper (IT) to copper (I) and this activity
could promote copper-mediated neurotoxicity. The expression of APP and APLP
2 in the brain suggests they could have an important direct or indirect rol
e in neuronal metal homeostasis. To examine this, we measured copper, zinc
and iron levels in the cerebral cortex, cerebellum and selected non-neurona
l tissues from APP (APP(-/-)) and APLP2 (APLP2(-/-)) knockout mice using at
omic absorption spectrophotometry. Compared with matched wild-type (WT) mic
e, copper levels were significantly elevated in both APP(-/-) and APLP2(-/-
) cerebral cortex (40% and 16%, respectively) and liver (80% and 36%, respe
ctively). Copper levels were not significantly different between knockout a
nd WT cerebellum, spleen or serum samples. There were no significant differ
ences observed between APP(-/-), APLP2(-/-) and WT mice zinc or iron levels
in any tissue examined. These findings indicate APP and APLP2 expression s
pecifically modulates copper homeostasis in the liver and cerebral cortex,
the latter being a region of the brain particularly involved in AD. Perturb
ations to APP metabolism and in particular, its secretion or release from n
eurons may alter copper homeostasis resulting in increased A beta accumulat
ion and free radical generation. These data support a novel mechanism in th
e APP/A beta pathway which leads to AD. (C) 1999 Elsevier Science B.V. All
rights reserved.